GENTA EYE DROPS

Indications

• Hydration therapy
• Solvent for intravenous medications
• Diluent for oral medications
• Rehydration in cases of fluid loss
• Topical applications for wound care

Dosage

Children: Refer to specific drug formulations for appropriate dosing, as the dosage will vary depending on the active ingredient in the aqueous solution.

Adults: Refer to specific drug formulations for appropriate dosing, as the dosage will vary depending on the active ingredient in the aqueous solution.

Mechanism of action

Aqueous solutions serve primarily as a medium for drug solubility and absorption. The mechanism of action depends on the active ingredient dissolved within the aqueous solution. For many drugs, the aqueous environment enhances bioavailability by allowing the active ingredients to dissolve and interact with biological membranes, facilitating their transport across cell barriers.

Pharmacodynamics

The pharmacodynamics of aqueous solutions are influenced by the solutes they contain. Generally, the dissolution of drugs in an aqueous medium can enhance their effectiveness by improving absorption rates, increasing peak plasma concentrations, and allowing for more predictable pharmacological effects. The specific pharmacodynamic response will depend on the nature of the solute and its interaction with the body’s receptors or enzymes.

Pharmacokinetics

The pharmacokinetics of aqueous solutions largely pertain to the dissolved substances. They are absorbed through various routes, such as gastrointestinal tract, intravenous administration, or topical application, depending on the formulation. The rate of absorption can vary based on the solute’s properties, such as molecular weight, lipophilicity, and the presence of other excipients. Distribution, metabolism, and excretion will also depend on the active ingredient within the aqueous solution.

Pregnancy

Aqueous solutions are generally regarded as safe for use during pregnancy, but the specific context and formulation should be considered.

Breast-feeding

Aqueous solutions are typically considered safe during breastfeeding, but caution is advised depending on the specific formulation.

Storage

Store at room temperature, away from direct sunlight and moisture. Ensure containers are tightly sealed.

Formulations

• Aqueous solution
• Aqueous gel
• Aqueous suspension

Indications

• Topical antiseptic
• Wound cleansing
• Surface disinfection
• Preservative in pharmaceutical formulations

Dosage

Children: For paediatric use, consult product-specific guidelines and refer to established dosing recommendations in appropriate pediatric references.

Adults: For topical use, apply a small amount to the affected area as needed. Consult product-specific guidelines for concentration and application frequency.

Mechanism of action

Benzalkonium chloride works by disrupting the cell membrane of microbes. It interacts with the lipid bilayer of the microbial cell membrane, leading to increased permeability and eventual cell lysis. This action is effective against a variety of microorganisms, including gram-positive and gram-negative bacteria as well as certain viruses and fungi.

Pharmacodynamics

Benzalkonium chloride exhibits dose-dependent antimicrobial activity. Its effectiveness varies based on concentration, exposure time, and the type of microorganism. At lower concentrations, benzalkonium chloride acts as a bacteriostatic agent, inhibiting microbial growth, while at higher concentrations, it has bactericidal effects, leading to cell death. The compound is also known to have some virucidal activity, particularly against enveloped viruses.

Pharmacokinetics

Benzalkonium chloride is poorly absorbed through the skin and mucous membranes, which limits systemic exposure. Its primary action is local, and it exerts its effects at the site of application. The compound is primarily eliminated from the body through the feces. The half-life and distribution can vary depending on the formulation and route of administration, but detailed pharmacokinetic data for benzalkonium chloride is limited due to its local use.

Adverse effects

• Skin irritation
• Burning sensation
• Allergic reactions
• Contact dermatitis

Precautions

• Use with caution in individuals with hypersensitivity to benzalkonium chloride
• Avoid contact with eyes and mucous membranes
• Prolonged use may lead to skin sensitization

Pregnancy

Limited data available, use with caution and only if the benefits outweigh risks.

Breast-feeding

Considered safe in small topical applications; consult healthcare provider for concerns.

Storage

Store at room temperature, away from direct sunlight and moisture.

Formulations

• Topical solutions
• Creams
• Gels
• Ointments

Indications

• Gastroesophageal reflux disease (GERD)
• Peptic ulcers
• Dyspepsia
• Irritable bowel syndrome
• Medication-induced gastric irritation

Dosage

Children: Refer to the BNF for Children for appropriate dosing.

Adults: Refer to the specific product guidelines or BNF for appropriate dosing.

Mechanism of action

Buffered medications work by neutralizing gastric acid, aiming to maintain a more neutral pH in the stomach or gastrointestinal tract. This action can facilitate better absorption of certain drugs that may be degraded or poorly absorbed in acidic environments. The buffering agents typically include compounds such as sodium bicarbonate or magnesium hydroxide, which react with gastric acid to decrease acidity.

Pharmacodynamics

The pharmacodynamic effects of buffered medications depend on the active pharmaceutical ingredient, but the buffering agents primarily function to mitigate the acidity of the stomach contents. This can lead to reduced irritation of the gastric mucosa and enhanced comfort for the patient. The overall effect is to promote a more favorable environment for drug absorption and decrease potential side effects associated with high acidity.

Pharmacokinetics

The pharmacokinetics of buffered medications can vary based on the specific active ingredient used. Generally, the buffering agents do not significantly alter the absorption, distribution, metabolism, or excretion of the drug but serve to improve solubility and stability. The onset of action may be faster for some formulations due to improved absorption in a less acidic environment. The buffering agents themselves are typically rapidly absorbed and excreted by the kidneys.

Pregnancy

Safety during pregnancy has not been established, consult healthcare provider before use.

Breast-feeding

Consult healthcare provider before use while breastfeeding.

Storage

Store in a cool, dry place away from direct sunlight.

Indications

• Severe infections caused by Gram-negative bacteria
• Urinary tract infections
• Bacteremia
• Sepsis
• Pneumonia
• Intra-abdominal infections
• Skin and soft tissue infections

Dosage

Adults: The usual dosage for adults is 3 to 5 mg/kg/day divided into 3 doses, given intravenously or intramuscularly. Adjustments should be made based on renal function and severity of infection.

Mechanism of action

Gentamicin acts by binding to the bacterial 30S ribosomal subunit, leading to misreading of mRNA and subsequent production of nonfunctional or toxic peptides. This disrupts protein synthesis and leads to bacterial cell death. The drug enters bacterial cells in a three-phase process: first, ionic binding occurs with the cell membrane, increasing permeability. Second, energy-dependent transport allows the drug to access its intracellular target. Third, concentration-dependent killing is observed as gentamicin accumulates within the cell, amplifying its effects on protein synthesis and membrane integrity.

Pharmacodynamics

Gentamicin exhibits concentration-dependent bactericidal activity, meaning that its efficacy increases with higher concentrations. The pharmacodynamic properties highlight the rapid and delayed bactericidal effects, with membrane disruption occurring immediately followed by impaired protein synthesis. The drug's action is particularly effective against aerobic Gram-negative bacteria, while its effectiveness is significantly reduced in anaerobic conditions.

Pharmacokinetics

Gentamicin is poorly absorbed from the gastrointestinal tract; thus, it is typically administered intravenously or intramuscularly. It has a volume of distribution that reflects extensive tissue penetration, particularly in renal and gastrointestinal tissues. The elimination half-life ranges from 2 to 3 hours in healthy individuals, but it can be prolonged in patients with renal impairment. The drug is primarily eliminated by renal excretion, with dosage adjustments required in cases of renal dysfunction.

Contra-indications

• Hypersensitivity to gentamicin or other aminoglycosides
• Severe renal impairment
• Myasthenia gravis

Adverse effects

• Nephrotoxicity
• Ototoxicity (hearing loss, balance disorders)
• Neuromuscular blockade
• Allergic reactions (rash, pruritus)
• Peripheral neuropathy

Interactions

• Increased risk of nephrotoxicity with other nephrotoxic agents (e.g., cisplatin, vancomycin)
• Increased risk of ototoxicity with loop diuretics (e.g., furosemide)
• Synergistic effects with beta-lactam antibiotics

Precautions

• Monitor renal function during treatment
• Use caution in patients with pre-existing hearing loss
• Adjust dosage in patients with renal impairment
• Consider potential drug interactions

Pregnancy

Gentamicin should be used during pregnancy only if clearly needed, due to potential risk of fetal harm.

Breast-feeding

Gentamicin is excreted in breast milk, but is generally considered safe. Monitor for possible effects on the infant.

Storage

Store in a cool, dry place, away from light. Do not refrigerate or freeze.

Formulations

• Injection (solution for injection)
• Topical ointment
• Eye drops

Indications

• Used as a medium for drug delivery
• Facilitates the formulation of various dosage forms
• Aids in the stability and solubility of active pharmaceutical ingredients

Dosage

Children: Refer to specific drug formulation guidelines as dosing will vary based on the active ingredient and intended use.

Adults: Refer to specific drug formulation guidelines as dosing will vary based on the active ingredient and intended use.

Mechanism of action

Vehicles do not have a pharmacological effect on their own; their primary role is to facilitate the delivery of the active ingredient. Their composition and properties can influence absorption, distribution, metabolism, and excretion of the API, thus affecting the overall efficacy of the drug formulation.

Pharmacodynamics

Pharmacodynamics of vehicles primarily relates to their role in enhancing the solubility and stability of the active ingredients. They can affect the release rate of the drug, its absorption in the body, and the overall therapeutic effect. The choice of vehicle can significantly impact the pharmacological activity of the API, especially in topical applications.

Pharmacokinetics

As vehicles are typically inert substances, they do not undergo significant metabolic processes in the body. However, their physical and chemical properties, such as viscosity, polarity, and pH, can influence the pharmacokinetics of the active ingredients they carry. This includes factors such as absorption rates and distribution within the body.

Mechanism of action

There are 3 key phases of aminoglycoside entry into cells. The first “ionic binding phase” occurs when polycationic aminoglycosides bind electrostatically to negatively charged components of bacterial cell membranes including with lipopolysaccharides and phospholipids within the outer membrane of Gram-negative bacteria and to teichoic acids and phospholipids within the cell membrane of Gram-positive bacteria. This binding results in displacement of divalent cations and increased membrane permeability, allowing for aminoglycoside entry. The second “energy-dependent phase I” of aminoglycoside entry into the cytoplasm relies on the proton-motive force and allows a limited amount of aminoglycoside access to its primary intracellular target - the bacterial 30S ribosome. This ultimately results in the mistranslation of proteins and disruption of the cytoplasmic membrane. Finally, in the “energy-dependent phase II” stage, concentration-dependent bacterial killing is observed. Aminoglycoside rapidly accumulates in the cell due to the damaged cytoplasmic membrane, and protein mistranslation and synthesis inhibition is amplified. The necessity of oxygen-dependent active transport explains why aminoglycosides are ineffective against anaerobic bacteria. Hence, aminoglycosides have both immediate bactericidal effects through membrane disruption and delayed bactericidal effects through impaired protein synthesis; observed experimental data and mathematical modeling support this two-mechanism model. Inhibition of protein synthesis is a key component of aminoglycoside efficacy. Structural and cell biological studies suggest that aminoglycosides bind to the 16S rRNA in helix 44 (h44), near the A site of the 30S ribosomal subunit, altering interactions between h44 and h45. This binding also displaces two important residues, A1492 and A1493, from h44, mimicking normal conformational changes that occur with successful codon-anticodon pairing in the A site. Overall, aminoglycoside binding has several negative effects including inhibition of translation, initiation, elongation, and ribosome recycling. Recent evidence suggests that the latter effect is due to a cryptic second binding site situated in h69 of the 23S rRNA of the 50S ribosomal subunit. Also, by stabilizing a conformation that mimics correct codon-anticodon pairing, aminoglycosides promote error-prone translation. Mistranslated proteins can incorporate into the cell membrane, inducing the damage discussed above. Aminoglycosides are usually bactericidal in action. Although the exact mechanism of action has not been fully elucidated, the drugs appear to inhibit protein synthesis in susceptible bacteria by irreversibly binding to 30S ribosomal subunits. /Aminoglycosides/ ... Aminoglycosides are aminocyclitols that kill bacteria by inhibiting protein synthesis as they bind to the 16S rRNA and by disrupting the integrity of bacterial cell membrane. Aminoglycoside resistance mechanisms include: (a) the deactivation of aminoglycosides by N-acetylation, adenylylation or O-phosphorylation, (b) the reduction of the intracellular concentration of aminoglycosides by changes in outer membrane permeability, decreased inner membrane transport, active efflux, and drug trapping, (c) the alteration of the 30S ribosomal subunit target by mutation, and (d) methylation of the aminoglycoside binding site. ... /Aminoglycosides/